

Emergent BioSolutions Inc.  
Form 8-K  
August 13, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): August 12, 2010  
Emergent BioSolutions Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-33137**  
(Commission File Number)

**14-1902018**  
(IRS Employer  
Identification No.)

**2273 Research Boulevard, Suite 400, Rockville,  
Maryland**

**20850**  
(Zip Code)

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(301) 795-1800**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Material Definitive Agreement.**

**Merger Agreement**

On August 12, 2010, Emergent BioSolutions, Inc. ( Emergent ), Trubion Pharmaceuticals, Inc. ( Trubion ), 35406 LLC (the Final Surviving Entity ), and 30333 Inc. (the Merger Sub ) (collectively, the Parties ) entered into an Agreement and Plan of Merger dated August 12, 2010 (the Merger Agreement ), pursuant to which, subject to the satisfaction or waiver of certain conditions, the Merger Sub will merge with and into Trubion (the Merger ), then promptly following the Merger, Trubion will merge with and into the Final Surviving Entity and the Final Surviving Entity will become a direct wholly owned subsidiary of Emergent.

Under the terms of the Merger Agreement, at the effective time of the Merger (the Effective Time ), each share of common stock, par value \$0.001 per share, of Trubion (the Trubion Common Stock ) issued and outstanding immediately prior to the Effective Time will be canceled and converted into the right to receive the following:

an amount in cash equal to \$1.365,

0.1641 shares of common stock, par value \$0.001 per share, of Emergent (the Emergent Common Stock ), and

one contingent value right (a CVR ) issued by Emergent, subject to and in accordance with the CVR Agreement described below.

No fractional shares of Emergent Common Stock will be issued in the Merger, and Trubion stockholders will receive cash in lieu of fractional shares, if any, of Emergent Common Stock.

All outstanding stock options ( Options ) of Trubion will be canceled at the Effective Time. Options with an exercise price of \$4.55 or above will be canceled and extinguished without further liability of the Parties. Holders of Options with an exercise price below \$4.55 will receive, for each share of Trubion Common Stock subject to such Option:

a cash payment equal to the difference between \$4.55 and the exercise price of the Option, and  
one CVR.

Trubion and Emergent s respective obligations to complete the Merger are subject to customary conditions, including:  
the approval of the Merger by Trubion s stockholders,  
the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act,  
and

the effectiveness of Emergent s Registration Statement on Form S-4 registering the issuance of the shares of Emergent Common Stock to be issued in the Merger.

The Merger Agreement generally prohibits Trubion from soliciting, initiating or intentionally encouraging competing proposals (the No-Shop Prohibition ). If Trubion terminates the Merger Agreement to enter into a definitive agreement for a Superior Competing Transaction (as defined in the Merger Agreement), Trubion must pay Emergent a termination fee of \$3.0 million (the Termination Fee ).

The Merger Agreement also provides for certain other termination rights for both Trubion and Emergent. Trubion may be required to pay Emergent the Termination Fee under other specified circumstances.

This summary of the Merger Agreement has been included, and the Merger Agreement has been included as an Exhibit hereto, to provide investors and security holders with information regarding its terms. This summary and the Merger Agreement are not intended to provide any other financial information regarding Trubion or Emergent. The representations, warranties and covenants contained in the Merger Agreement were made only for the purposes of that agreement and as of specific dates; were solely for the benefit of the parties to the Merger Agreement; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of Trubion or Emergent. Moreover, any information covering the subject matter of the representations, warranties and covenants may change after the date

of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosure by Trubion or Emergent.

**Contingent Value Rights Agreement**

Emergent, Trubion and Mellon Investor Services, as rights agent, entered into a Contingent Value Rights Agreement, dated as of August 12, 2010, (the CVR Agreement ) governing the terms of the CVRs. The CVRs are not transferable and do not have any voting or dividend rights. No interest accrues on any amounts payable to any holders of CVRs and the CVRs do not represent any equity or ownership interest in Emergent or in any other Parties. A holder of a CVR is entitled to receive a pro rata portion of each of the following contingent payments following the achievement of future development milestones (under Trubion s collaboration agreements with Pfizer Inc. and Abbott Laboratories) as set forth below:

Milestone Events	Applicable Payments
Initiation of dosing in the first Phase 3 clinical study for the first major indication for CD20 candidate	\$6.25 million
Initiation of dosing in the first Phase 3 clinical study for the second major indication for CD20 candidate	\$5.0 million
Initiation of dosing in the first Phase 2 clinical study for a non CD20 target	\$0.75 million
Initiation of the first Phase 2 clinical study for TRU-016	\$1.75 million
Initiation of the first Phase 3 clinical study in oncology indication for TRU-016	\$15.0 million
Release of TRU-016 manufactured for use in clinical studies.	\$10.0 million

The total potential payment under the CVRs is \$38.75 million over a 36-month period following the Effective Time. Emergent has agreed to use commercially reasonable efforts to achieve all of the milestones set forth above as soon as practicable and to cause the payment of the related milestone payments in order to be able to disburse the corresponding CVR payment amounts.

**Support Agreement**

Emergent entered into Support Agreements, dated August 12, 2010 (each, a Support Agreement ) with certain significant holders of Trubion Common Stock holding, in the aggregate, approximately 41% of the outstanding Trubion Common Stock as of July 31, 2010 (the Principal Holders ), pursuant to which such Principal Holders agreed, subject to the terms thereof, to vote a portion of their shares of Trubion Common Stock equaling approximately 35% of the outstanding shares of Trubion Common Stock in favor of the approval and adoption of the Merger Agreement and the transactions contemplated thereby, and against, among other things, Competing Transactions (as defined in the Merger Agreement). Each Principal Holder also agreed to the No-Shop Prohibition as discussed above. Finally, each Principal Holder granted Emergent an irrevocable proxy to vote the specified amount of shares subject to the Support Agreements.

The Support Agreements also limit the ability of the Principal Holders to sell or otherwise transfer their shares of Trubion Common Stock. The Support Agreements automatically terminate if the Merger Agreement terminates.

**Lock-up Agreement**

Emergent also entered into Lock-up Agreements, dated August 12, 2010 (the Lock-up Agreements ) with the Principal Holders, pursuant to which the Principal Holders agreed to the following transfer restrictions (the Lock-up Restrictions ) relating to Emergent Common Stock during the Lock-up Period (as defined in the Lock-up Agreement):

First 90 days from the Effective Time no transfers (other than permitted transfers, such as a bona fide gift, certain estate planning and affiliate transactions) allowed.

After 90 days to 180 days from the Effective Time the Principal Holders may transfer up to 25% of their respective shares of Emergent Common Stock.

Edgar Filing: Emergent BioSolutions Inc. - Form 8-K

After 180 days to 270 days from the Effective Time the Principal Holders may transfer up to 50% of their respective shares of Emergent Common Stock.

---

After 270 days to 360 days from the Effective Time the Principal Holders may transfer up to 75% of their respective shares of Emergent Common Stock.

After 360 days from the Effective Time the Lock-up Restrictions expire and the Principal Holders may freely transfer all of their respective shares of Emergent Common Stock.

Notwithstanding the foregoing, (A) if a Parent Acceleration Event occurs prior to the date that is one hundred eight (180) days after the Effective Time (such date, the Six Month Anniversary), the restrictions set forth in clauses (1) and (2) above will continue to apply to the Stock Merger Consideration except that (y) for a period of one hundred eighty (180) days after the Effective Time, the undersigned may take any such action referred to in clauses (1) and (2) above in respect of up to fifty percent (50%) of the Stock Merger Consideration received by the undersigned at the Effective Time and (z) after the Six Month Anniversary, the restrictions imposed by this Letter Agreement shall no longer apply, and (B) if a Parent Acceleration Event occurs after the Six Month Anniversary, the restrictions imposed by this Letter Agreement shall lapse immediately upon the occurrence of such Parent Acceleration Event. Parent Acceleration Event shall be deemed to have occurred if, at any time during the applicable period, both (1) the closing sale price per share for shares of Parent Common Stock (as defined in the Merger Agreement) on the New York Stock Exchange for any 20 trading days (which need not be consecutive) during a consecutive 30 calendar day period shall exceed 120% of the Parent Average Stock Price (as defined in the Merger Agreement) and (2) Parent shall issue any shares of Parent Common Stock (as defined in the Merger Agreement) in connection with any financing transaction, including any private placement or public offering.

#### **Additional Information and Where to Find It**

This communication is being made in connection with the proposed merger (the Merger) among Emergent BioSolutions Inc. (Emergent), Trubion Pharmaceuticals, Inc. (Trubion) and certain of Emergent's direct and indirect wholly-owned subsidiaries. Emergent intends to file with the Securities and Exchange Commission (the SEC) a registration statement on Form S-4, which will contain a prospectus relating to the securities Emergent intends to issue in the proposed Merger. Trubion intends to file a preliminary proxy statement in connection with the proposed Merger and to mail a definitive proxy statement and other relevant documents to Trubion's stockholders. Stockholders of Emergent and Trubion and other interested persons are advised to read, when available, the registration statement and Trubion's preliminary proxy statement, and amendments thereto, and definitive proxy statement in connection with Trubion's solicitation of proxies for the special meeting to be held to approve the Merger because these documents will contain important information about Trubion, Emergent and the proposed Merger. The definitive proxy statement will be mailed to stockholders as of a record date to be established for voting on the Merger. Stockholders will also be able to obtain a copy of the documents filed with the SEC, without charge, once available, at the SEC's website at <http://www.sec.gov> or by directing a request to: Emergent BioSolutions Inc., Attn: Investor Relations, 2273 Research Boulevard, Suite 400, Rockville, Maryland 20850, or Trubion Pharmaceuticals, Inc., Attention: Investor Relations, 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.

#### **Participants in Solicitation**

Emergent, Trubion and their respective directors and officers may be deemed participants in the solicitation of proxies from Trubion's stockholders. Information regarding Emergent's directors and officers is available in Emergent's proxy statement for its 2010 annual meeting of stockholders and its 2009 annual report on Form 10-K, which were filed with the SEC and are available at the SEC's website at <http://www.sec.gov>. Information regarding Trubion's directors and officers is available in Trubion's proxy statement for its 2010 annual meeting of stockholders and its 2009 annual report on Form 10-K, which were filed with the SEC and are available at the SEC's website at <http://www.sec.gov>. Information regarding Trubion's directors and officers will also be contained in Trubion's proxy statement in connection with the Merger when it becomes available. Emergent's and Trubion's stockholders may obtain additional information about the interests of Trubion's directors and officers in the Merger by reading Trubion's proxy statement when it becomes available.

#### **Item 9.01. Financial Statements and Exhibits.**

##### **(d) Exhibits.**

2.1 Agreement and Plan of Merger, dated August 12, 2010

Edgar Filing: Emergent BioSolutions Inc. - Form 8-K

10.1 Contingent Value Rights Agreement, dated August 12, 2010

10.2 Form of Support Agreement, dated August 12, 2010

10.3 Form of Lock-up Agreement, dated August 12, 2010

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August \_\_\_\_,  
2010

EMERGENT BIOSOLUTIONS INC.

By: /s/ R. Don Elsey

R. Don Elsey  
Chief Financial Officer

---

INDEX TO EXHIBITS

<b>Exhibit No.</b>	<b>Description</b>
2.1	Agreement and Plan of Merger, dated August 12, 2010
10.1	Contingent Value Rights Agreement, dated August 12, 2010
10.2	Form of Support Agreement, dated August 12, 2010
10.3	Form of Lock-up Agreement, dated August 12, 2010